TWM
GILD icon

TriaGen Wealth Management’s Gilead Sciences GILD Stock Holding History

TriaGen Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,450
Closed -$1.46M – 200
2026
Q1 		$1.46M Sell
10,450
-990
-9% -$139K 0.4% 59
2025
Q4 		$1.4M Sell
11,440
-40
-0.3% -$4.86K 0.36% 68
2025
Q3 		$1.27M Buy
+11,480
New +$1.3M 0.33% 77
2021
Q2 		– Sell
-18,300
Closed -$1.18M – 192
2021
Q1 		$1.18M Sell
18,300
-200
-1% -$12.9K 0.68% 51
2020
Q4 		$1.08M Buy
+18,500
New +$1.12M 0.63% 55

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TriaGen Wealth Management's GILD Position: Q2 2026 in Review

TriaGen Wealth Management sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 10,450 shares — an estimated $1.46M sold.

TriaGen Wealth Management first reported a position in GILD in Q4 2020 and held it in 5 quarters. The position peaked at $1.46M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • TriaGen Wealth Management reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • TriaGen Wealth Management sold 10,450 Gilead Sciences shares in Q2 2026, an estimated $1.46M.
  • TriaGen Wealth Management first reported a position in Gilead Sciences in Q4 2020 and held it in 5 quarters.
  • TriaGen Wealth Management's Gilead Sciences position peaked at $1.46M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on TriaGen Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.